|
KMID : 0338420090240020113
|
|
The Korean Journal of Internal Medicine
2009 Volume.24 No. 2 p.113 ~ p.122
|
|
|
Cilostazol Protects Endothelial Cells Against Lipopolysaccharide-Induced Apoptosis Through ERK1/2- and P38 MAPK-Dependent Pathways
|
|
Lim Jong-Hoon
Woo Jae-Seok
Shin Yung-Woo
|
|
|
Abstract
|
|
|
Background/Aims: We examined the effects of cilostazol on mitogen-activated protein kinase (MAPK) activity and its relationship with cilostazol-mediated protection against apoptosis in lipopolysaccharide (LPS)-treated endothelial cells.
Methods: Human umbilical vein endothelial cells (HUVECs) were exposed to LPS and cilostazol with and without specific inhibitors of MAPKs; changes in MAPK activity in association with cell viability and apoptotic signaling were investigated.
Results: Cilostazol protected HUVECs against LPS-induced apoptosis by suppressing the mitochondrial permeability transition, cytosolic release of cytochrome c, and subsequent activation of caspases, stimulating extracellullar signal-regulated kinase (ERK1/2) and p38 MAPK signaling, and increasing phosphorylated cAMPresponsive element-binding protein (CREB) and Bcl-2 expression, while suppressing Bax expression. These cilostazol-mediated cellular events were effectively blocked by MAPK/ERK kinase (MEK1/2) and p38 MAPK inhibitors.
Conclusions: Cilostazol protects HUVECs against LPS-induced apoptosis by suppressing mitochondriadependent apoptotic signaling. Activation of ERK1/2 and p38 MAPKs, and subsequent stimulation of CREB phosphorylation and Bcl-2 expression, may be responsible for the cellular signaling mechanism of cilostazolmediated protection.
|
|
|
KEYWORD
|
|
|
Cilostazol, Protection, Endothelial Cells, Apoptosis, Extracellular signal-Regulated MAP Kinases 1/2, p38 Mitogen-Activated Protein Kinase
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|